{"id":"bgb-a445","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Tumor lysis syndrome"},{"rate":null,"effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BGB-A445 selectively inhibits B-cell lymphoma 2 (Bcl-2) family proteins, which are frequently overexpressed in hematologic malignancies and prevent programmed cell death. By blocking these anti-apoptotic signals, the drug restores the ability of cancer cells to undergo apoptosis. This mechanism is particularly effective in cancers dependent on Bcl-2 for survival.","oneSentence":"BGB-A445 is a Bcl-2 inhibitor that promotes apoptosis in cancer cells by blocking anti-apoptotic proteins.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:43:20.214Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia (CLL)"},{"name":"Small lymphocytic lymphoma (SLL)"},{"name":"Follicular lymphoma"}]},"trialDetails":[{"nctId":"NCT04164199","phase":"PHASE3","title":"Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeOne Medicines","startDate":"2019-12-19","conditions":"Advanced Malignancies","enrollment":404},{"nctId":"NCT05661955","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2023-01-09","conditions":"Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma","enrollment":113},{"nctId":"NCT05635708","phase":"PHASE2","title":"A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2023-03-07","conditions":"Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer","enrollment":400},{"nctId":"NCT06029127","phase":"PHASE2","title":"A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2023-10-23","conditions":"Non-Small Cell Lung Cancer","enrollment":35},{"nctId":"NCT04215978","phase":"PHASE1","title":"Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"BeiGene","startDate":"2020-01-30","conditions":"Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":204}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Gimistotug"],"phase":"phase_3","status":"active","brandName":"BGB-A445","genericName":"BGB-A445","companyName":"BeiGene","companyId":"beigene","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BGB-A445 is a Bcl-2 inhibitor that promotes apoptosis in cancer cells by blocking anti-apoptotic proteins. Used for Chronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL), Follicular lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}